ArticleInternational medical case reports journal2026
Novel Nerve-Selective Treatment for Managing Knee Pain from Symptomatic Osteoarthritis: A Preliminary Case Series.
Article in International medical case reports journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Introduction: Between conservative treatments and total knee arthroplasty, adequate interventional pain management options for osteoarthritis of the knee (OAK) are limited. BXT-786 is a novel nerve-selective biomaterial intended to provide prolonged analgesia when delivered around the nerve branches that innervate the knee joint for use in patients with symptomatic OAK. Methods: We conducted a nonrandomized, single-cohort, open-label pilot feasibility study at a single site in Australia (ANZCTR.org ID: ACTRN12624000250538p) between April and December 2024. The primary objective of the current study was to evaluate the safety and tolerability of BXT-786 version 3.0 in four patients with symptomatic OAK. The secondary objective was to evaluate the preliminary analgesic performance of BXT-786 in managing knee pain associated with OAK. Results: BXT-786 treatment showed a reduction in knee pain that was observed approximately 4 to 9 days post-procedure. Compared to the baseline, the subjects saw a 79.7% decrease in average numerical rating scale pain scores at 6 months. Anecdotal information indicated that most subjects experienced pain relief, which enabled increased mobility, improved use of the affected knee, and greater engagement in daily life activities. BXT-786 treatment did not affect motor functions or result in device-related serious adverse events. Conclusion: This study demonstrates feasibility of BXT-786 version 3.0 in four patients with symptomatic OAK. The observed preliminary clinical benefit of nerve-selective treatment also supports further investigation as a potential non-systemic, non-pharmacologic, and minimally invasive intervention option for long-term pain relief.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.